Zoek een klinische studie of trial
Andere zoekoptie(s)
14 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Gefinancierd door een IRDiRC-lid = 
; Member of a ERN = 
Nationale klinische studie(s)
CANADA
Ontario
TORONTO
A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression
Toronto General Hospital
University Health Network (UHN)
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT (Completed)
Institution: Information not provided - CA
DUITSLAND
Baden-Württemberg
STUTTGART
MATRix - IELSG43 : High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial -DE-
Klinikum Stuttgart - Katharinenhospital
Klinik für Hämatologie, Onkologie und Palliativmedizin
DUITSLAND
Nordrhein-Westfalen
ESSEN
Clinical Phase III Trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic Stem Cell Transplantation in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) considered ineligible to standard conditioning regimens - DE
Universitätsklinikum Essen
Klinik für Knochenmarktransplantation
FRANKRIJK
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FR
Institution: Information not provided - FR
FRANKRIJK
AUVERGNE-RHONE-ALPES
CLERMONT-FERRAND
Rice NK : Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma (Phase II)
CHU de Clermont-Ferrand - Hôpital d'Estaing
Service de Thérapie cellulaire et Hématologie clinique
FRANKRIJK
ILE-DE-FRANCE
PARIS
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation
Hôpital Necker-Enfants Malades
Service d'Hématologie adulte
FRANKRIJK
PAYS DE LA LOIRE
NANTES
Cloric : A Phase II Open-Label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-Risk AML, MDS or ALL
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
ITALIË
PIEMONTE
TORINO
Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Center Trial
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
S.C. di Ematologia
SPANJE
Cataluña
BARCELONA
A Randomized, National, Open-label, Multicenter, Phase III Trial Studying Induction Therapy With Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-dose Chemotherapy With Melphalan-200 (MEL-200) Versus Busulfan-melphalan (BUMEL), and Consolidation With VRD-GEM in Patients Under 65 Years Old With Newly-diagnosed, Symptomatic Multiple Myeloma - ES (Completed)
Hospital Clínic de Barcelona
Servicio de Hematología
SPANJE
Comunidad Valenciana
VALENCIA
A Phase II Trial of Autologous Stem Cell Transplant in Multiple Myeloma Patients Following Conditioning with Intravenous Busulfan and Melphalan (terminated)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
USA
Alabama
BIRMINGHAM
Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen (Phase II) (Completed)
University of Alabama at Birmingham
USA
California
DUARTE
Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen (Phase II) (Completed)
City of Hope
City of Hope National Medical Center
USA
Michigan
ANN ARBOR